Oral Arbidol Treatment for Allergic Rhinitis Evaluating Safety and Effectiveness in Adults

What this Trial Is About

Allergic rhinitis AR is a non-infectious inflammatory condition of the nasal lining triggered by allergens and mediated by Immunoglobulin E. It is a common chronic respiratory disease that affects patients quality of life and has economic impacts. Current treatments mainly involve nasal medications like corticosteroids and antihistamines, but many patients do not achieve satisfactory results. Arbidol, a medicine used for influenza, is being studied for its potential to inhibit molecular targets involved in ARs development to improve treatment effectiveness and convenience. Participants will receive oral Arbidol Hydrochloride Tablets at a dose of 0.2g per day for two weeks. This study includes one treatment group and does not involve placebo or masking. The treatment period lasts 14 days, during which researchers will analyze the effect of Arbidol on molecular and inflammation biomarkers related to AR. During the study, participants will undergo evaluations measuring protein and mRNA levels of molecular biomarkers in nasal cells and inflammation markers in nasal fluid at 14 days. Daily nasal symptom scores will also be recorded over the treatment period. Participants will follow the medication and visit schedule, record symptom scales, medication use, and any adverse events. The study runs until June 2025, with ongoing monitoring of efficacy and safety outcomes.

Efficacy and Safety of Arbidol in the Treatment of Allergic Rhinitis